On December 1, 2025 OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale patient-derived biology, reported that data from its development candidate, ONC001, has been selected for an oral presentation at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including highly resistant subsets. The ADC was developed using OncoPrecision’s proprietary discovery engine, which integrates large-scale, patient-derived biology and AI-enhanced high-throughput screening to reveal the most actionable cellular vulnerabilities. This process enabled the identification of a lead antibody with high affinity against an overlooked target, alongside the optimal ADC payload and linker chemistry to minimize off-target toxicity and collateral damage to healthy hematopoiesis. ONC001 is advancing through IND-enabling studies and represents a differentiated approach to overcoming monocyte-driven resistance.
Preclinical data to be presented by Dr. Gastón Soria, Co-Founder and Chief Scientific Officer, will highlight:
Selective engagement of patient-derived CMML and AML cells
Robust activity in samples resistant to current standard-of-care therapies
Compelling in vivo efficacy across heterotopic and orthotopic models
"The selection of ONC001 for an oral presentation at ASH (Free ASH Whitepaper) underscores the strength of this fundamentally new therapeutic approach," said Tarek Zaki, Co-Founder & Chief Executive Officer of OncoPrecision. "ONC001 is designed to specifically target resistance mechanisms that drive certain aggressive blood cancers, offering a new way to overcome common treatment failures. We look forward to sharing this data with the global hematology community and to continuing discussions with prospective development and strategic partners."
"ONC001 is the direct result of our platform’s ability to integrate insights from patient-derived biology with rational target selection and payload matching," said Dr. Gastón Soria. "Although CD64 has long been acknowledged as a biomarker of monocytic leukemia, no approved or clinical-stage assets have successfully exploited it as a therapeutic target. Our platform unveiled that an ADC modality is the optimal path to achieve this."
Oral Presentation Details
Title: ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection
Presenter: Gastón Soria, PhD, Co-Founder & Chief Scientific Officer, OncoPrecision
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML
Date: Saturday, December 6, 2025
Session Time: 4:00 PM – 5:30 PM
Presentation Time: 5:15 PM – 5:30 PM
Location: OCCC – Valencia Room W415D
(Press release, OncoPrecision, DEC 1, 2025, View Source [SID1234661029])